Notice2023-17672
Collaboration Opportunity To Develop a Vaccine Against Nicotine or Arecoline
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
August 17, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The Cancer Prevention Program of the National Cancer Institute (NCI) is seeking a partner in the private sector to develop a vaccine directed against nicotine or a related molecule called arecoline, with the goal of reducing or eliminating the craving of such substance(s) in smokers or betel nut users.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 158 (Thursday, August 17, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 158 (Thursday, August 17, 2023)]
[Notices]
[Pages 56027-56028]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-17672]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Collaboration Opportunity To Develop a Vaccine Against Nicotine
or Arecoline
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Cancer Prevention Program of the National Cancer Institute
(NCI) is seeking a partner in the private
[[Page 56028]]
sector to develop a vaccine directed against nicotine or a related
molecule called arecoline, with the goal of reducing or eliminating the
craving of such substance(s) in smokers or betel nut users.
FOR FURTHER INFORMATION CONTACT: Inquiries relating to this
collaboration opportunity should be directed to: Michael Pollack,
Ph.D., Supervisory Technology Transfer Manager, NCI Technology Transfer
Center, 9609 Medical Center Drive, Room 1E530, Rockville, MD 20850 (for
overnight mail) or Bethesda, MD 20892 (for regular mail), Telephone:
(240) 276-5530; Facsimile: (240) 276-5504; Email:
<a href="/cdn-cgi/l/email-protection#6818070404090b0305280509010446060100460f071e"><span class="__cf_email__" data-cfemail="7606191a1a17151d1b361b171f1a58181f1e58111900">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: The NCI has expertise in the latest
technology of vaccine development and agents to enhance immune
responses to vaccines, and NCI has the ability to participate in
vaccine preclinical and clinical studies. The NCI is seeking a partner
with expertise in this area of anti-smoking research and development.
Dated: August 11, 2023.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2023-17672 Filed 8-16-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on August 17, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.